This is the JAAD Journal Review podcast for September 2026. The Journal of the American Academy of Dermatology has given us four pieces this month — an ethics column on image-guided superficial radiation therapy, two "Game Changer" commentaries revisiting notable prior JAAD publications, and a full original cohort study out of the UK Biobank linking metabolic syndrome to pathologic scarring. Let's get into it.

First up is an Ethics Journal Club entry — this is a reader-question-and-answer column, not a data paper, so there's no methods or results section to walk through, just an ethical argument being built. The question posed is how dermatologists should ethically counsel patients as image-guided superficial radiation therapy, abbreviated IGSRT, expands into office-based practice. The columnist's answer is essentially a case for caution grounded in evidence gaps and financial conflict of interest. The background here: superficial radiation therapy, or SRT, has a long track record as a reasonable option for low-risk keratinocyte carcinomas in patients who are poor surgical candidates or who decline surgery. What's new is the "image-guided" add-on — ultrasound-based depth estimation bolted onto conventional SRT. The columnist notes that the American Society for Radiation Oncology has explicitly stated this imaging component is not medically necessary and has no demonstrated impact on dose selection or outcomes. The literature supporting IGSRT is characterized as short-term, retrospective, industry-sponsored, with substantial loss to follow-up and, notably, no histologic confirmation of tumor clearance — which for anyone trained in margin-based cure verification should raise an eyebrow. The ethical crux is that IGSRT courses typically run multiple fractions over several weeks, with costs driven largely by repeated imaging that doesn't appear to change dosimetry. Recent Medicare local coverage determinations have actually deemed the imaging component "not reasonable" in several jurisdictions, even while covering conventional SRT itself for appropriately selected nonsurgical patients. The piece frames this squarely as a resource stewardship issue and a conflict-of-interest issue — practices that both own the radiation equipment and generate the billing have a financial stake that patients deserve to understand, even without needing exact reimbursement figures disclosed. The practical takeaway for a Mohs surgeon is straightforward and, honestly, validating: surgery remains first-line for the overwhelming majority of keratinocyte carcinomas; SRT is a legitimate fallback for genuine nonsurgical candidates; but IGSRT's imaging premium isn't currently justified by evidence, and if you're referring patients into these office-based radiation pathways, or fielding questions about them, you should be counseling with that evidence gap in mind rather than assuming the fancier acronym means a better standard of care.

Next, two "Game Changer" pieces — these are short retrospective commentaries written by other physicians reflecting on the impact of an original JAAD article, so we'll treat them as the brief narrative pieces they are rather than full studies.

The first revisits a randomized, investigator-blinded, controlled trial on early postoperative water exposure after cutaneous surgery. The commentator's framing is that postoperative wound care instructions — the classic "keep it dry for 24 to 48 hours" rule — have long been dogma rather than data, and this trial tested that dogma directly. The original study, by Samaan and colleagues, randomized 437 patients undergoing cutaneous surgery to either early water exposure at 6 hours postop or standard dry-dressing care through 48 hours. Since this is genuinely a comparative randomized trial, it's worth noting briefly why that design fits the question: randomization balances unmeasured confounders like wound location, patient comorbidities, and healing capacity across both arms, so any difference in outcomes can be attributed to the water exposure timing itself rather than who happened to get assigned to which group; and investigator blinding on outcome assessment guards against bias when judging something as subjective as cosmetic outcome or scar quality. The result, per the commentary, was unambiguous: no difference between groups in infection, bruising, hematoma, or scarring, and cosmesis and quality-of-life measures came out equivalent, with the early-exposure group benefiting from getting back to normal bathing sooner. This one is genuinely practice-changing and immediately actionable — the traditional 48-hour dry-time restriction appears to be unnecessary dogma, and you can tell patients they may get the wound wet within a few hours in appropriate scenarios, improving their comfort and quality of life without adding complication risk.

The second Game Changer piece is more of a cautionary read. It revisits an article examining the commercially available 40-gene expression profiling test used to predict metastatic risk and outcomes in cutaneous squamous cell carcinoma. This commentary isn't describing a new trial — it's summarizing an analytic critique of the test's biological and statistical underpinnings, so there's no methods-versus-results arc to narrate, just a set of findings worth flagging. The key points: of the forty genes in the panel, nineteen have not been clearly associated with cutaneous squamous cell carcinoma biology at all, and well-established driver mutations in the disease — TP53 and NOTCH1 and NOTCH2 — aren't represented in the panel. On performance, the test showed higher specificity than traditional staging in some risk groups, but lower sensitivity, and accuracy reported across studies was variable. The takeaway here is emphatically not practice-changing in the sense of adopting anything new — it's the opposite. It's a reminder to treat this gene expression test's risk stratification as adjunctive at best, not as a replacement for your clinical staging judgment, and to stay alert to the gap between commercial availability and validated clinical utility. Any decision to escalate or de-escalate management based on this assay alone should be viewed with real skepticism until the evidence base matures.

Now the main course — a full original study, a prospective cohort analysis from the UK Biobank asking whether metabolic syndrome is associated with excessive scarring, meaning keloids and hypertrophic scars grouped together.

Background: keloids and hypertrophic scars are driven by dysregulated fibroblast proliferation and extracellular matrix deposition, current treatments — intralesional steroids, antimetabolites, radiation, excision — are limited by high recurrence, and the authors note that metabolic disturbances are already known to impair wound healing and drive fibrosis in other organs. Prior small clinical observations hinted that individual metabolic syndrome components like hypertension and dyslipidemia might correlate with scarring, but nobody had looked at metabolic syndrome as a composite entity in a large population. That's the gap this paper fills.

Methods: they used data from just over 466,000 UK Biobank participants after exclusions, defining metabolic syndrome by the standard harmonized criteria — three or more of elevated waist circumference, elevated blood pressure, elevated fasting glucose or HbA1c, elevated triglycerides, or low HDL cholesterol. Excessive scarring was captured via specific ICD-10 codes for keloid and hypertrophic scar diagnoses, since the authors note these two entities can't reliably be teased apart in coded electronic records, so they were analyzed as a combined outcome — a pragmatic choice given the data source, though one that blurs a distinction we as dermatologic surgeons care about clinically.

The core analytic technique here is multivariable Cox proportional hazards regression, and it's worth spending a moment on why this is the right tool. Cox regression is built for exactly this kind of data: a large population followed forward in time, where people enter the study, some develop the outcome at various points, some are censored because they die or are lost to follow-up or the study ends before they develop scarring. Rather than just comparing raw proportions at one point in time, which would ignore who was followed longer or shorter, a Cox model compares the instantaneous risk — the hazard — of developing excessive scarring at each moment among everyone still under observation and still at risk, and asks how that hazard differs between exposure groups, here metabolic syndrome versus not. It does this without requiring you to specify the exact shape of how risk changes over time, which is the "proportional hazards" assumption — that the ratio of risk between groups stays roughly constant even as absolute risk rises or falls with age. The output, the hazard ratio, is essentially the relative risk of the event at any given moment, adjusted for whatever covariates get built into the model. Here the authors ran three sequential models, progressively adding adjustment for age, sex, race, education, and deprivation index, then further for body mass index, smoking, drinking, exercise, and diet — a stepwise adjustment strategy that lets you see whether an association survives after progressively ruling out competing explanations, which is about as much causal inference as you can responsibly claim from observational cohort data.

Results: over a median follow-up of roughly thirteen and a half years, 714 people developed excessive scarring out of the full cohort — so this remains a rare outcome in absolute terms, worth keeping in mind before over-weighting the relative risk numbers. After full adjustment, metabolic syndrome carried about a 28% increase in the hazard of excessive scarring, and that was statistically significant. Breaking down the individual components: increased waist circumference carried roughly a 40% increased risk, hypertension about a 30% increased risk, high triglycerides about a 25% increased risk, and low HDL cholesterol about a 25 to 30% increased risk — all statistically significant. Fasting glucose or diabetes status, notably, was not significantly associated with scarring risk at all, which is a useful negative finding — it suggests the link isn't simply about glycemic control but more about the adiposity, blood pressure, and lipid axis of the syndrome. There was also a clear dose-response signal: risk climbed progressively with the number of metabolic syndrome criteria a person met. The findings held up when the authors substituted two alternative standard definitions of metabolic syndrome, which is a reasonable sensitivity check confirming the association isn't an artifact of how they drew the diagnostic line. Stratified analyses suggested the association was stronger in men, in people under 60, and in White participants — though given the UK Biobank's demographics, the non-White subgroup was small, so that stratification should be read cautiously rather than as a strong signal that non-White individuals are protected.

Discussion and limitations: the authors' own stated limitation is notably sparse — they flag that this hasn't been verified in other populations, which matters more than it might sound, because the UK Biobank is overwhelmingly White, European, and comparatively older at enrollment, so generalizing to populations with higher baseline keloid prevalence, such as individuals of African or Asian descent, is genuinely uncertain. Beyond what the authors state, a few things are worth flagging yourself: this is an observational cohort, so despite the layered adjustment, residual confounding is possible, and reverse causation can't be fully excluded, since chronic inflammatory fibrotic states and metabolic dysfunction plausibly influence each other bidirectionally. The reliance on ICD-10 coding to capture scarring, rather than clinician-confirmed diagnosis or histology, also means some misclassification is likely, and lumping keloids with hypertrophic scars — clinically distinct entities with different biology and racial predilection — limits how precisely you can interpret the mechanism.

Practical takeaway: this is interesting and biologically plausible, not yet practice-changing in the sense of altering how you counsel a patient sitting in your chair about scar risk before an excision. You're not going to order a lipid panel before a routine closure. But it's a reasonable talking point for patients with recognized risk factors for excessive scarring — a history of keloids, planned elective procedures in high-tension areas — where mentioning that better metabolic health, weight, blood pressure, and lipid control might modestly lower their fibrotic risk fits comfortably into the kind of holistic counseling we already do, and it opens a legitimate avenue for future prospective or mechanistic work rather than demanding any change to your surgical planning today.

That wraps this September's rundown — an ethics reminder to keep radiation therapy decisions evidence-driven and free of financial conflict, two Game Changer look-backs, one validating that we can finally let our patients shower without fear, the other cautioning restraint around a commercial gene expression assay in squamous cell carcinoma, and a large biobank study tying metabolic syndrome to a modestly higher risk of pathologic scarring. Thanks for listening, and we'll see you next month.